What's Happening?
Kelun-Biotech announced promising translational research results for sacituzumab tirumotecan (sac-TMT) in combination with osimertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). The study, published in Cancer Cell, demonstrates
that sac-TMT can delay resistance to EGFR tyrosine kinase inhibitors by targeting TROP2 in drug-tolerant persister cells. The company is conducting a Phase III trial to evaluate the efficacy of this combination therapy. Sac-TMT has already been approved in China for advanced EGFR-mutant NSCLC following progression on TKI therapy, showing significant benefits in progression-free and overall survival.
Why It's Important?
The development of sac-TMT as a combination therapy with osimertinib represents a significant advancement in treating EGFR-mutant NSCLC, a challenging cancer type with limited treatment options. By delaying drug resistance, sac-TMT could improve patient outcomes and extend the effectiveness of existing therapies. This research highlights the potential of antibody-drug conjugates in oncology, offering a targeted approach to cancer treatment. The success of sac-TMT could lead to new treatment paradigms and expand therapeutic options for patients with EGFR-mutant NSCLC, addressing a critical unmet medical need.
What's Next?
Kelun-Biotech will continue its Phase III trial to assess the long-term benefits and safety of sac-TMT in combination with osimertinib. The company is also exploring sac-TMT's potential in earlier-stage NSCLC and other solid tumors. Regulatory submissions and potential approvals in additional markets could follow, expanding the drug's availability. Kelun-Biotech's ongoing research and development efforts aim to solidify its position in the global oncology market, with sac-TMT as a cornerstone of its innovative drug portfolio.
